Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CART123 cells + Ruxolitinib |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CART123 cells | CART123 cells are T-cells engineered to express a chimeric antigenic receptor (CAR) targeting CD123 and linked to 4-1BB and CD3zeta signaling domains, which potentially enhance antitumor immune response and inhibit tumor growth (PMID: 24596416). | |||
| Ruxolitinib | Jakafi | INCB 18424|INCB018424|INCB18424 | JAK1 Inhibitor - ATP competitive 5 JAK2 Inhibitor - ATP competitive 15 | Jakafi (ruxolitinib) is an inhibitor of protein tyrosine kinases JAK1 and JAK2, thus resulting in reduced inflammation and reduced proliferation (PMID: 22474318). Jakafi (ruxolitinib) is FDA approved to treat bone marrow cancer, specifically intermediate or high-risk myelofibrosis (FDA.gov) |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06768476 | Phase I | CART123 cells + Ruxolitinib | CART123 + Ruxolitinib in Relapsed/Refractory AML (AML) | Recruiting | USA | 0 |